Regulatory News:

Vetoquinol (Paris:VETO):

Vetoquinol published its calendar of financial communication for 2022.

 

January 20, 2022

2021 Annual revenues (after market)

March 24, 2022

2021 Annual results (before market)

April 13, 2022

2022 First quarter revenues (after market)

May 19, 2022

Annual shareholders’ meeting

June 7, 2022

Dividend distribution

July 20, 2022

2022 First semester revenues (after market) 

September 15, 2022

2022 First semester results (after market)

October 12, 2022

2022 Third quarter revenues (after market)

January 18, 2023

2022 Annual revenues (after market) 

Next update: 2021 Annual revenues, January 20th, 2022 after market close

ABOUT VETOQUINOL Vetoquinol is a leading global animal health company that supplies drugs and non-medicinal products for the livestock (cattle and pigs) and pet (dogs and cats) markets. As an independent pure player, Vetoquinol designs, develops and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region. Since its foundation in 1933, Vetoquinol has pursued a strategy combining innovation with geographical diversification. The Group’s hybrid growth is driven by the reinforcement of its product portfolio coupled with acquisitions in high potential growth markets. Vetoquinol employed 2,540 people as of September 30th, 2021. Vetoquinol has been listed on Euronext Paris since 2006 (symbol: VETO). The Vetoquinol share is eligible for the French PEA and PEA-PME personal equity plans.

VETOQUINOL

Investor Relations Fanny Toillon Tel.: +33 (0)3 84 62 59 88 relations.investisseurs@vetoquinol.com

KEIMA COMMUNICATION

Investor & Media Relations Emmanuel Dovergne Tel.: +33 (0) 1 56 43 44 63 emmanuel.dovergne@keima.fr

Vetoquinol (EU:VETO)
Graphique Historique de l'Action
De Juin 2022 à Juil 2022 Plus de graphiques de la Bourse Vetoquinol
Vetoquinol (EU:VETO)
Graphique Historique de l'Action
De Juil 2021 à Juil 2022 Plus de graphiques de la Bourse Vetoquinol